Crescendo Bioscience To Present Multiple Studies At 2014 EULAR Meeting
Published: Jun 11, 2014
SALT LAKE CITY, June 10, 2014 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (Nasdaq:MYGN), today announced that Vectra® DA data will be featured in eight posters at the 2014 European League Against Rheumatism (EULAR) Annual Meeting, June 11–14, 2014, in Paris, France. Vectra DA is a quantitative, objective multi-biomarker test to measure disease activity in patients with rheumatoid arthritis (RA). The Vectra DA test offers insight into the biological processes that drive disease activity to help rheumatologists manage RA and improve patient care.
Help employers find you! Check out all the jobs and post your resume.